Maravai LifeSciences (MRVI) Tops Q3 EPS by 3c

Maravai LifeSciences (NASDAQ: MRVI) reported Q3 EPS of $0.37, $0.03 better than the analyst estimate of $0.34. Revenue for the quarter came in at $191.3 million versus the consensus estimate of $195.4 million.

For earnings history and earnings-related data on Maravai LifeSciences (MRVI) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• JPMorgan Downgrades JD Logistics Inc (2618:HK) (JDLGF) to Neutral
• BMO Capital Resumes Global Net Lease (GNL), Upgrades to Outperform